9-10-2024

# **Newsletter of the Gallbladder Cancer Registry**

Dear members of the IHPBA,

We're incredibly excited to see that the registry has gained so much traction in the last few months, even over the summer period. Even more centres across the world have joined our team and we're happy to see our network grow rapidly. We'd like to thank all the new collaborators for their enthusiasm and participation. We'd also like to welcome Femke Atsma, senior epidemiologist and methodologist to the study coordination team. As the academic year is in full swing, we'd like to update you on the progress of the study and our plans and aims for the coming few months.

## Sincerely,

Dr. Philip de Reuver and dr. Elise de Savornin Lohman


On behalf of the Gallbladder Cancer Registry steering committee.


## Medscinet data completion

In total, 1488 patients have been registered in the Medscinet database. Baseline data on 629 participants has been completed to a sufficient degree. We'd like to provide a special thanks to our Spanish collaborators and regional coordinator Mikel Prieto Calvo in particular, as the Spanish centers have a near one hundred percent completion rate. Great work! The graphs below provide an overview of the total number of inclusions (Figure 1) as well as the number of inclusions per T stage (Figure 2). The Medscinet database has now been taken down. In the future, all data collection will be conducted in CastorEDC.

#### **New partners**

Before the summer, we had twelve participating centers in the renewed, prospective registry. We're proud to announce that we now have **thirty-eight sites** including patients worldwide! We're aiming to increase this number even more by the end of the year. If any of your colleagues are interested in joining, please refer them to our website <a href="http://www.gbcregistry.com">http://www.gbcregistry.com</a>.





A total of 327 patients have already been included in the new database. Our top contributor is dr. Diego Hinjosa Ugarte (Mexico), personally responsible for the inclusion of 161 patients. Other top contributors are dr. Antonio Gomes (Portugal) with 36 patients and dr. Andrea Belli (Italy) with 26 patients. Congratulations and thank you so much for this amazing effort!

The graphs below provide an overview of the number of patients included throughout the past months (Figure 3) as well as the number of patients included per institute (Figure 4).

Figure 3: Total inclusions in CastorEDC






Figure 4: Inclusions per institute

Site	Total
University of Colombo	4
Bucharest Oncological Institute	1
Instituto Nacional del Cancer Rosa Emilia Perez de Tavares	4
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	161
University of Newcastle	3
Instituto Oncologico Dr. Heriberto Pieter	6
National Cancer Institute Pascale Foundation	26
Hippocrates University Hospital	11
Vito Fazzi Hospital	11
Etablissement Hospital University	20
AIIMS Rishikesh	16
Hospital Prof. Dr. Fernando Foncesca	36
Medanta the Medicity	4
Ankara Bilkent City Hospital	7
University hospital Halle (Saale)	1
Complejo Asistencial Dr. Sótero del Río	9
Integrated University Hospital of Verona	1
Prof Dr Suleyman Yalcın City Hospital	3
General Hospital for Diseases of the Guatemalan Social Security Institute	1

## Aims for the end of 2024

In the Delphi consensus study published recently by prof. Jagannath (<u>link</u>), no agreement could be established on the required extent of liver resection in T3 gallbladder cancer. Using the combined prospective and retrospective registry data, we aim to publish a paper on this topic by comparing survival outcomes of T3 patients according to extent of liver- and bile duct resection.

All participants from centers who've contributed patients will be mentioned as an author in the collaborative. Enclosed in the e-mail by which you received this newsletter, a research proposal has been appended. We feel that this is a beautiful start and we hope to provide a feasible, comprehensive example of potential uses of our extensive dataset.

In addition, we'd like to invite all participants to write their own research proposals using the data from the retrospective dataset. Proposals will be screened by the Steering Committee and data will be provided if the research proposal is found suitable.

# Use of own data

The new data management system allows all local investigators to track their number of inclusions live, and compare it to the others in the database. Moreover, every investigator is able to download their own data for personal use. In order to utilize data from other centers, a research proposal needs to be sent to the steering committee and approved by all members.

# Interested?

Please visit our website: <a href="www.gbcregistry.com">www.gbcregistry.com</a>, or send an e-mail to the study coordinators (<a href="Philip.dereuver@radboudumc">Philip.dereuver@radboudumc</a> or <a href="mailto:elisedesavorninlohman@gmail.com">elisedesavorninlohman@gmail.com</a> )

Visit our website: www.gbcregistry.com